Elan approaches breakeven on Tysabri gains
This article was originally published in Scrip
Executive Summary
Elan narrowed its net loss to within striking distance of breakeven for the first quarter as revenues of its multiple sclerosis drug Tysabri (natalizumab) grew globally. Along with full-year revenue growth the Irish company's CEO Shane Cooke forecasts an operating profit this year for the first time in several years.